First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors

A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer. Twenty-five patients with histologically confi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-02, Vol.22 (4), p.877-885
Hauptverfasser:	Meulendijks, Didier, Jacob, Wolfgang, Martinez-Garcia, Maria, Taus, Alvaro, Lolkema, Martijn P, Voest, Emile E, Langenberg, Marlies H G, Fleitas Kanonnikoff, Tania, Cervantes, Andres, De Jonge, Maja J, Sleijfer, Stefan, Soerensen, Morten Mau, Thomas, Marlene, Ceppi, Maurizio, Meneses-Lorente, Georgina, James, Ian, Adessi, Celine, Michielin, Francesca, Abiraj, Keelara, Bossenmaier, Birgit, Schellens, Jan H M, Weisser, Martin, Lassen, Ulrik N
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Analgesics - pharmacology Analgesics - therapeutic use Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Colorectal Neoplasms - drug therapy Colorectal Neoplasms - metabolism Female Humans Male Maximum Tolerated Dose Middle Aged Receptor, ErbB-3 - antagonists & inhibitors Receptor, ErbB-3 - metabolism Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!